. Author manuscript; available in PMC: 2019 Mar 1.

Published in final edited form as: Clin Cancer Res. 2017 Sep 25;24(5):1019–1029. doi: 10.1158/1078-0432.CCR-17-1792

Table 1.

Summary of patient response to the combination of vaccination and decitabine treatment.

	Negative	Positive
Induction of NY-ESO-1 Expression
Pre-Treatment (N = 9)	8	1
Post 1^st Cycle (N = 9)	2	7
Post 4^th Cycle (N = 7)	4	3
	Absent	Present
NY-ESO-1 Specific CD4+ T-Lymphocyte Response
Pre-Treatment (N = 9)	6	3
EOS (N = 7)	1	6
NY-ESO-1 Specific CD8+ T-Lymphocyte Response
Pre-Treatment (N = 9)	9	0
EOS (N = 7)	3	4
	Seronegative	Seropositive
NY-ESO-1 Specific Antibody Titers
Pre-Treatment (N = 9)	9	0
EOS (N = 7)	5	2

For all patients on study, NY-ESO-1 expression in CD11b+ myeloid cells was serially assessed throughout the study using nested RT-PCR. Results are summarized at diagnosis, following the 1^st cycle of therapy (n = 9) and at the end of the study (n = 7). NY-ESO-1-specific immune responses were assessed at diagnosis (n = 9) and at the EOS (n = 7). NY-ESO-1 expression was measured in peripheral CD11b⁺ myeloid cells using nested RT-PCR. NY-ESO-1-specific CD4⁺ and CD8⁺ lymphocyte responses were measured using ELISPOT assay. Levels of NY-ESO-1-specific antibodies were measured in sera using ELISA. Assays were performed as described in Materials and Methods.